Fate Therapeutics (FATE) Misses Q3 EPS by 2c, Beats on Revenues

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $930 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Fate Therapeutics (FATE) PT Raised to $3.50 at Wells Fargo